Lee Hartwell will be retiring from his post as president and director of the Fred Hutchinson Cancer Research Center in June 2010, the Hutch announced last week.
Hartwell, who turns 70 in October, has led the Hutch since 1997. In a statement, he said that after 12 years, "It's time for new leadership."
Hartwell was a recipient of the Nobel Prize in physiology or medicine in 2001. Upon his retirement he will become director emeritus at FHCRC and continue research into early cancer detection and science education. He will also remain as chairman of the executive committee of the Partnership for Personalized Medicine, an Arizona-based effort to improve healthcare and reduce healthcare costs.
A search for Hartwell's successor has begun, said Doug Walker, chair of the Hutch's board of trustees. A search committee has been formed, headed by Steve Davis, senior advisory at McKinsey & Co., a management consulting firm, and a board member at FHCRC. A consultant will be selected to assist in the search, the Hutch said.
Thomas Caskey was appointed the chairman of Genome Canada's board, the agency said this week.
His appointment became effective June 18.
Caskey was appointed vice-chair in 2008. He currently is CEO of the Brown Foundation Institute of Molecular Medicine, which studies diseases at the cellular and molecular levels using protein and DNA technologies. He also is a professor at the Institute of Molecular Medicine at the University of Texas Health Sciences Center.
He previously was managing director of Cogene Biotech Ventures, a venture capital fund, and chairman of the department of molecular and human genetics at Baylor College of Medicine. He was senior vice president, human genetics and vaccines discovery at Merck Research Laboratories and president of the Merck Genome Research Institute.